These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 28159737)

  • 1. Stem and progenitor cell alterations in myelodysplastic syndromes.
    Shastri A; Will B; Steidl U; Verma A
    Blood; 2017 Mar; 129(12):1586-1594. PubMed ID: 28159737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deconstructing innate immune signaling in myelodysplastic syndromes.
    Varney ME; Melgar K; Niederkorn M; Smith M; Barreyro L; Starczynowski DT
    Exp Hematol; 2015 Aug; 43(8):587-598. PubMed ID: 26143580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.
    Schinke C; Giricz O; Li W; Shastri A; Gordon S; Barreyro L; Bhagat T; Bhattacharyya S; Ramachandra N; Bartenstein M; Pellagatti A; Boultwood J; Wickrema A; Yu Y; Will B; Wei S; Steidl U; Verma A
    Blood; 2015 May; 125(20):3144-52. PubMed ID: 25810490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.
    Barreyro L; Will B; Bartholdy B; Zhou L; Todorova TI; Stanley RF; Ben-Neriah S; Montagna C; Parekh S; Pellagatti A; Boultwood J; Paietta E; Ketterling RP; Cripe L; Fernandez HF; Greenberg PL; Tallman MS; Steidl C; Mitsiades CS; Verma A; Steidl U
    Blood; 2012 Aug; 120(6):1290-8. PubMed ID: 22723552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations.
    Will B; Zhou L; Vogler TO; Ben-Neriah S; Schinke C; Tamari R; Yu Y; Bhagat TD; Bhattacharyya S; Barreyro L; Heuck C; Mo Y; Parekh S; McMahon C; Pellagatti A; Boultwood J; Montagna C; Silverman L; Maciejewski J; Greally JM; Ye BH; List AF; Steidl C; Steidl U; Verma A
    Blood; 2012 Sep; 120(10):2076-86. PubMed ID: 22753872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stem cell concepts in myelodysplastic syndromes: lessons and challenges.
    Woll PS; Jacobsen SEW
    J Intern Med; 2021 May; 289(5):650-661. PubMed ID: 33843081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
    Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
    J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
    Chesnais V; Arcangeli ML; Delette C; Rousseau A; Guermouche H; Lefevre C; Bondu S; Diop M; Cheok M; Chapuis N; Legros L; Raynaud S; Willems L; Bouscary D; Lauret E; Bernard OA; Kosmider O; Pflumio F; Fontenay M
    Blood; 2017 Jan; 129(4):484-496. PubMed ID: 27856460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stem cell origin of myelodysplastic syndromes.
    Elias HK; Schinke C; Bhattacharyya S; Will B; Verma A; Steidl U
    Oncogene; 2014 Oct; 33(44):5139-50. PubMed ID: 24336326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.
    Balderman SR; Li AJ; Hoffman CM; Frisch BJ; Goodman AN; LaMere MW; Georger MA; Evans AG; Liesveld JL; Becker MW; Calvi LM
    Blood; 2016 Feb; 127(5):616-25. PubMed ID: 26637787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TLR2/6 signaling promotes the expansion of premalignant hematopoietic stem and progenitor cells in the NUP98-HOXD13 mouse model of MDS.
    Monlish DA; Greenberg ZJ; Bhatt ST; Leonard KM; Romine MP; Dong Q; Bendesky L; Duncavage EJ; Magee JA; Schuettpelz LG
    Exp Hematol; 2020 Aug; 88():42-55. PubMed ID: 32652111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the role of the microenvironment in MDS?
    Calvi LM; Li AJ; Becker MW
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101113. PubMed ID: 31779976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
    Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
    Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice.
    Wei Y; Zheng H; Bao N; Jiang S; Bueso-Ramos CE; Khoury J; Class C; Lu Y; Lin K; Yang H; Ganan-Gomez I; Starczynowski DT; Do KA; Colla S; Garcia-Manero G
    Blood Adv; 2018 Oct; 2(19):2491-2504. PubMed ID: 30275007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes.
    Abbas S; Kini A; Srivastava VM; M MT; Nair SC; Abraham A; Mathews V; George B; Kumar S; Venkatraman A; Srivastava A
    Blood Cells Mol Dis; 2017 Jul; 66():37-46. PubMed ID: 28822917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron overload may promote alteration of NK cells and hematopoietic stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes.
    Hua Y; Wang C; Jiang H; Wang Y; Liu C; Li L; Liu H; Shao Z; Fu R
    Int J Hematol; 2017 Aug; 106(2):248-257. PubMed ID: 28405919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal CD25 expression on hematopoietic cells in myelodysplastic syndromes.
    Liu P; Jiang H; Che M; Fu R; Wang H; Li L; Zhang W; Tao J; Gao S; Shao Z
    Leuk Res; 2018 Apr; 67():12-16. PubMed ID: 29407181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
    Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
    Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes?
    Tavakkoli M; Chung SS; Park CY
    Expert Opin Ther Targets; 2018 May; 22(5):381-383. PubMed ID: 29637789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.
    Ganan-Gomez I; Yang H; Ma F; Montalban-Bravo G; Thongon N; Marchica V; Richard-Carpentier G; Chien K; Manyam G; Wang F; Alfonso A; Chen S; Class C; Kanagal-Shamanna R; Ingram JP; Ogoti Y; Rose A; Loghavi S; Lockyer P; Cambo B; Muftuoglu M; Schneider S; Adema V; McLellan M; Garza J; Marchesini M; Giuliani N; Pellegrini M; Wang J; Walker J; Li Z; Takahashi K; Leverson JD; Bueso-Ramos C; Andreeff M; Clise-Dwyer K; Garcia-Manero G; Colla S
    Nat Med; 2022 Mar; 28(3):557-567. PubMed ID: 35241842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.